U.S. MARKETS FOR MINIMALLY INVASIVE BENIGN PROSTATIC HYPERPLASIA AND PROSTATITIS THERAPIES

74 Pages | 15 Exhibits | 2015 Analysis | Forecasts Through 2019 Product Family: Market Reports




OVERVIEW:
In the United States (U.S.) benign prostatic hyperplasia (BPH) and prostatitis currently affect over 10 million men, lowering quality of life with painful symptoms that can be difficult to manage. The U.S. market for minimally invasive products for the treatment of BPH and prostatitis includes pharmaceutical and minimally invasive surgical systems aimed at treating the symptoms of BPH/prostatitis. New therapies in development offer the potential to change the way that symptomatic BPH and prostatitis patients live their lives, improving quality of life through adequate management of symptoms. Pharmaceuticals used in the treatment of symptoms play an integral role in the treatment of urological conditions, and often represent the first-line of treatment in symptomatic patients. Medical management will continue to have a major impact on the treatment of patients during the forecast period covered by this report, representing the primary competitive therapy to the minimally invasive therapeutic products segment. The overall market for minimally invasive surgical systems used in the treatment of BPH and prostatitis was valued at $168.8 million in 2014. Over the forecast period covered by this report, total sales are expected to increase at a compound annual growth rate of 3.2%, reaching an estimated $197.2 million by the year 2019. Minimally invasive therapies for the treatment of symptomatic BPH account for the overwhelming majority of total sales for this market.

This report will cover:

  • Minimally invasive and pharmaceutical products for the treatment of enlarged prostates due to BPH or prostatitis;
  • Procedure and market forecasts for the years 2014 to 2019;
  • Key factors influencing the growth of individual product markets;
  • Estimated market shares and sales among major U.S. suppliers;
  • Major supplier product portfolio analysis in individual product markets; and,
  • Emerging technology therapies that could potentially change the treatment paradigm of BPH and prostatitis.


TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Methodology

1. CLINICAL OVERVIEW

1.1 Benign Prostatic Hyperplasia
	1.1.1 Symptoms
	1.1.2 Diagnosis
	1.1.3 Treatment
1.2 Prostatitis
	1.2.1 Symptoms
	1.2.2 Diagnosis
	1.2.3 Treatments

Exhibit 1-1: Overview of the Lower Urinary Tract
Exhibit 1-2: Summary of Symptoms for Types of Prostatitis

2. MINIMALLY INVASIVE PRODUCTS FOR BENIGN PROSTATIC HYPERPLASIA

2.1 Established Therapeutic Approaches
	2.1.1 Watchful Waiting
	2.1.2 Drug Therapy
		2.1.2.1 Clinical Development
		2.1.2.2 Market Forecast
	2.1.3 Surgical Treatment
		2.1.3.1 Transurethral Resection of the Prostate
		2.1.3.2 Transurethral Incision of the Prostate
		2.1.3.3 Stents
		2.1.3.4 Market Forecast
	2.1.4 Minimally Invasive Therapy
		2.1.4.1 Transurethral Microwave Thermotherapy
		2.1.4.2 Transurethral Needle Ablation
		2.1.4.3 Laser-Based Therapy
		2.1.4.4 Other Energy-Based Therapies
		2.1.4.5 Prostate Artery Embolization
		2.1.4.6 Prostate Implant
		2.1.4.7 Clinical Development
		2.1.4.8 Market Forecast
		2.1.4.9 Market Drivers and Limiters
		2.1.4.10 Competitive Analysis

Exhibit 2-1: Ongoing Clinical Trials for Pharmaceutical Therapies for the Treatment of Symptomatic BPH
Exhibit 2-2: 2015, Average Cost of Select Pharmaceuticals for Treatment of Benign Prostatic Hyperplasia Symptoms
Exhibit 2-3: Transurethral Resection of the Prostate, Procedure Volumes Forecast, 2014-2019
Exhibit 2-4: Transurethral Resection of the Prostate, Market Forecast, 2014-2019
Exhibit 2-5: Minimally Invasive Treatments for Benign Prostatic Hyperplasia, Procedure Volumes Forecast, 2014-2019
Exhibit 2-6: Minimally Invasive Treatments for Benign Prostatic Hyperplasia, Market Forecast, 2014-2019
Exhibit 2-7: 2014, Minimally Invasive Microwave/RF Thermotherapy Systems Market, Share by Supplier
Exhibit 2-8: 2014, Minimally Invasive Laser-based Therapy Systems Market, Share by Supplier

3. MINIMALLY INVASIVE PRODUCTS FOR PROSTATITIS

3.1 Established Therapeutic Approaches
	3.1.1 Drug Therapy
		3.1.1.1 Anti-infectives
		3.1.1.2 Anti-Inflammatory and Analgesic Agents
		3.1.1.3 Narcotic Drugs
		3.1.1.4 Alpha-Adrenergic Blockers
		3.1.1.5 Clinical Development
		3.1.1.6 Market Analysis
	3.1.2 Conservative Non-Pharmacologic Therapy
	3.1.3 Surgical Treatment
	3.1.4 Minimally Invasive Thermotherapy
		3.1.4.1 Microwave Thermotherapy
		3.1.4.2 Water-Induced Thermotherapy
3.2 Market Forecast

Exhibit 3-1: Treatment Algorithm for Patients with CBP and CPPS
Exhibit 3-2: Select Anti-infective Agents for the Treatment of Bacterial Prostatitis
Exhibit 3-3: Prostatitis Treatment, Advantages and Disadvantages of Minimally Invasive Thermotherapy
Exhibit 3-4: Minimally Invasive Prostatitis Treatments, Procedure Volumes Forecast, 2014-2019
Exhibit 3-5: Minimally Invasive Prostatitis Treatments, Market Forecast, 2014-2019


APPENDIX:  COMPANY LISTING

BIBLIOGRAPHY


COMPANIES COVERED:

  1. Allergan
  2. American Medical Systems/ Endo Pharmaceuticals
  3. Ausio Pharmaceuticals
  4. Boston Scientific
  5. Biolitec
  6. Convergent Laser Technologies
  7. Eli Lilly
  8. GlaxoSmithKline
  9. Gold Coast Therapeutics
  10. HistoSonics
  11. Insys Therapeutics
  12. LISA Laser Products
  13. Lumenis
  14. Materia Medica Holding
  15. Medifocus
  16. NeoTract
  17. Nymox Pharmaceutical Corporation
  18. Olympus America/ Olympus
  19. Pfizer
  20. Pierre Fabre Medicament
  21. PROCEPT BioRobotics
  22. ProstaLund
  23. Takeda
Contact Us

Need help finding medtech research? Let us help you!